ACE2 microbody

**ACE2 microbody** is an experimental antiviral **recombinant fusion protein** developed in academic research at **NYU Langone Health**. It consists of the **ACE2 ectodomain** fused to **Fc domain 3 of the immunoglobulin heavy chain** and incorporates an **H345A** substitution that inactivates ACE2 catalytic activity without materially reducing affinity for the **SARS-CoV-2 spike protein**. The molecule is designed to act as a soluble decoy receptor that binds spike and blocks viral attachment and entry, and published preclinical work reported inhibition of SARS-CoV-2 pseudovirus entry and live virus replication in vitro and in a mouse model, with greater potency than soluble ACE2. It has been proposed as a potential therapeutic for **COVID-19** and for broader coronavirus threats, but no commercial brand name, formal industrial sponsor, or clinical-stage development program has been clearly identified from the provided information.

Other names

H345A ACE2 microbodyH-345A ACE2 microbodyH 345A ACE2 microbodyACE2-Fc domain 3 microbodyACE-2-Fc domain 3 microbodyACE 2-Fc domain 3 microbody